LAUSR

In a recent study published in Nature, Zhang et al. [1] revealed a new epigenetic mechanism for restraining tumor intrinsic immunogenicity: Lysine demethylase 5B (KDM5B) recruits SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) to repress the transcription of transposable elements (TEs) by H3K9me3 modification, while TE de-repression by targeting KDM5B consequently activated nucleic acid sensing pathways and antigen presentation to elicit tumor intrinsic immunity which enhanced host anti-tumor immune response. Immune evasion is an important strategy for tumor survival and progression. Cancer immunotherapies have been developed to block immune escape by manipulating the host immune system to recognize and eventually eliminate tumor cells, which have shown outstanding efficacy in multiple cancers [2]. However, a majority of patients fail to respond to immunotherapies, largely due to tumor evasion through tumor-intrinsic resistance or immune exhaustion [3]. One of the efficient strategies to overcome immunotherapy resistance is to unleash tumorintrinsic immunity, mainly including: (1) upregulating